CytoDyn (STU:296) Other Current Receivables: €0.00 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:296 CytoDyn Inc STU:296
34 GF Score
Price €0.19
! 1 Warning Sign
View Full Analysis

What is CytoDyn Other Current Receivables?

CytoDyn STU:296 -3.03% 34 Other Current Receivables is €0.00 Mil as of Feb. 2026. GuruFocus rates STU:296 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

CytoDyn's Other Current Receivables for the quarter that ended in Feb. 2026 was €0.00 Mil.

CytoDyn's annual Other Current Receivables stayed the same from May. 2023 (€0.00 Mil) to May. 2024 (€0.00 Mil) but then increased from May. 2024 (€0.00 Mil) to May. 2025 (€1.77 Mil).

CytoDyn Other Current Receivables Related Terms

CytoDyn Other Current Receivables Historical Data

* Premium members only.

The historical data trend for CytoDyn's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Other Current Receivables Chart

CytoDyn Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.77

CytoDyn Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.92 1.77 0.00 0.00 0.00
STU:296
34GF Score
CytoDyn Inc STU:296
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.00 Mil mean?
CytoDyn (STU:296) has a Other Current Receivables of €0.00 Mil as of Feb. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on CytoDyn and its competitors.
Is CytoDyn's Other Current Receivables too high?
CytoDyn's current Other Current Receivables is €0.00 Mil. Overall, CytoDyn has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Other Current Receivables compare to VSTM and IRD?
CytoDyn's Other Current Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on CytoDyn and its competitors. CytoDyn's current Other Current Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current Other Current Receivables of €0.00 Mil. The current Other Current Receivables is €0.00 Mil. CytoDyn's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For CytoDyn (STU:296), the current Other Current Receivables is €0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges CYDY:USA
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
34GF Score

Get the complete analysis for STU:296

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price